Lung Cancer
Conference Coverage
Risk factors for severe immune-related AEs identified
A nationwide cohort study of more than 14,000 patients finds combination immune checkpoint inhibitor therapy, younger age, and a lung cancer...
Conference Coverage
Lung cancer: Proton beam radiotherapy likely reduces cardiovascular events
A retrospective study shows lower rates of transient ischemic attack and MI with proton beam radiotherapy.
From the Journals
Adding cetuximab to afatinib provides no benefit in EGFR-mutant NSCLC
Survival outcomes were similar whether patients received afatinib alone or afatinib plus cetuximab.
From the Journals
Real-world results with checkpoint inhibitors found inferior to trial results
Data suggest real-world survival is worse than survival in clinical trials.
Conference Coverage
National lung cancer screening guidelines may miss younger African American individuals at high risk
Retrospective analysis finds many lung cancer patients would not have counted as eligible for low-dose CT under guidelines that are being...
News from the FDA/CDC
FDA OKs combination immunotherapy for first-line mesothelioma treatment
Combination nivolumab and ipilimumab has now been approved as first-line treatment in mesothelioma.
Conference Coverage
High-dose TRT: A new standard of care for LS-SCLC?
Though it conferred a significant improvement in survival without increasing toxicity, high-dose thoracic radiotherapy should not be the new...
Conference Coverage
Apatinib plus gefitinib: Better PFS but more toxicity
Adding apatinib to gefitinib prolonged progression-free survival by 3.5 months.
Conference Coverage
Sotorasib is a ‘triumph of drug discovery’ in cancer
Conference Coverage
Lorlatinib: Another first-line option for ALK-positive NSCLC?
Lorlatinib bested crizotinib as first-line therapy for ALK-positive non–small cell lung cancer.